Delivering faster answers to more patients
One integrated diagnostics ecosystem
Mayo Clinic Laboratories provides serious or complex laboratory testing to advance patient care worldwide. For over 50 years, we’ve helped physicians answer the toughest clinical questions with confidence and empowered hospitals to elevate care in their communities. Through one integrated diagnostics ecosystem powered by Mayo Clinic, we deliver trusted, timely answers to patients around the globe.
“We focus on delivering accurate and timely results but also serving as a compass for providers and their patients to be connected to the right therapies no matter where they are in the world.”
William Morice II, M.D., Ph.D., president and CEO, Mayo Clinic Laboratories
Patient-centered innovation

Learn more

Learn more

Learn more
News and updates
The latest
Specialized immunofluorescence testing helps uncover rare autoimmune blistering diseases, identify underlying cancers, and guide precise treatment, improving diagnostic accuracy and outcomes for patients with challenging skin disorders.
Collaborating with Mayo Clinic Laboratories, UNC Health streamlined neuroimmunology test ordering — eliminating outmoded testing and elevating diagnostic accuracy.
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
Supported by Mayo Clinic’s holistic, precision medicine approach, which included advanced genetic insights, access to an emerging therapy, and tailored treatment monitoring, Giana Urse gained the confidence and clarity she needed to pursue her dream of becoming a dog trainer.
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
New wtRNA-seq test detects fusions in 1,445 genes with high accuracy, improving cancer diagnosis, treatment decisions, and clinical trial eligibility.
A young dancer from Minnesota thrives with a rare blood disorder, thanks to resilience, family advocacy, and lifesaving lab medicine.
Mayo Clinic Laboratories is applying AI where it helps most today, strengthening daily workflows while keeping experts firmly in control. From faster specimen intake and triage to data‑informed scheduling, first‑pass support for complex analyses, draft interpretive reporting, and reliable digital pathology quantification, teams use AI to organize information, reduce repetitive steps, and improve consistency. Human‑in‑the‑loop oversight, fit‑for‑workflow design, and regulatory‑aware communication keep the focus on safe, practical gains that benefit patients, clinicians, and laboratorians.
Viral and pharmacogenomic testing help clinicians detect infection early, tailor immunosuppression, and improve long-term outcomes for organ transplant recipients.
After months of misdiagnoses, Tom Heisler found answers at Mayo Clinic, where advanced renal pathology revealed IgG4-related disease and led to his recovery.
Artificial intelligence (AI) is reshaping laboratory medicine, not as a distant promise, but as a practical tool improving diagnostics, workflows, and quality. Through collaborative development, rigorous validation, and a commitment to ethical innovation, Mayo Clinic Laboratories is implementing AI-driven solutions that enhance precision, reduce turnaround times, and empower laboratorians to focus on what matters most: patient care.
A random urine test panel aids in diagnosing mast cell activation syndrome (MCAS), a complex condition often misdiagnosed due to overlapping symptoms. The panel improves access, speeds up diagnosis, and enables individualized treatment by detecting key mast cell mediators.
After mysterious neurological symptoms began in 2010, Brad Karon, M.D., Ph.D., was diagnosed with paraneoplastic syndrome, a rare condition that led to groundbreaking research and test development at Mayo Clinic. Years later, pulmonary fibrosis and a double lung transplant would test him once again — and redefine his resilience.